Condition
Fibrosis and Cirrhosis of Liver
Total Trials
4
Recruiting
1
Active
1
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
Termination Rate
0.0%
0 terminated out of 4 trials
Late-Stage Pipeline
25%
1 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
2Total
P 1 (1)
P 4 (1)
Trial Status
Unknown2
Recruiting1
Not Yet Recruiting1
Clinical Trials (4)
Showing 4 of 4 trials
NCT06823713Phase 1Recruiting
RTX001 Autologous Engineered Macrophages for Liver Cirrhosis
NCT06616103Not Yet Recruiting
Quantitative CT Imaging Parameters for Assessing Hepatic Steatosis in CHB
NCT04626492UnknownPrimary
Quantitative MRI Imaging in Diffuse Liver Diseases
NCT03798119Phase 4Unknown
TAF Switch in F3/4 CHB pt With Partial Response to NUC (ESTAB-AFPVR)
Showing all 4 trials